Viral Vector and Plasmid DNA: Technologies and Global Markets

Target Date - September 2019| Analyst - Anuj Pathak| Code - BIO192A

Viral Vector and Plasmid DNA: Technologies and Global Markets

Notify Me

Report Includes
  • An overview of global markets and technologies for viral vector and plasmid DNA
  • Analyses of global market trends, with data from 2018, 2019, and projections of compound annual growth rates (CAGRs) through 2024
  • Detailed description about gene therapy, its role in treatment of several heritable and acquired diseases and development of viral vectors and plasmid DNA for gene therapy
  • Investigational studies on potential viruses for gene therapy such as adenoviruses, retroviruses, poxviruses, adeno-associated viruses (AAV), and herpes simplex viruses (HSV)
  • Knowledge about innovative plasmid DNA vaccines which can be used for immunization of humans against infectious diseases and cancers.
  • Information on various gene therapies such as Kymriah, Yescarta, Luxturna, Strimvelis and Imlygic and researches going on viral vector-based gene therapies
  • Details about development of CAR-T cell therapies for the treatment of acute lymphoblastic leukemia (ALL) and large B cell lymphoma
  • A look at the innovations in pharmaceutical and biotechnology companies and research & development programs in stem cell-based therapies and gene therapies
  • Assessment of regulatory challenges, vector characterization & QC testing in the viral vector and plasmid DNA industry
  • Comprehensive company profiles of key players in the market
Get Notified when New Reports are published
CUSTOM

 

MEMBERSHIP